The FDA just authorized Eli Lilly’s antibody treatment for emergency use to treat the coronavirus

  • US health officials just approved pharmaceutical company Eli Lilly’s COVID-19 antibody therapy for emergency use. 
  • The drugmaker said that, in clinical trials, the treatment successfully reduced virus levels, symptoms, and hospitalizations in patients with mild to moderate cases, with no serious side effects.
  • The drug is similar to the experimental antibody treatment that President Donald Trump received when he was hospitalized at Walter Reed National Military Medical Center in October. 
  • The FDA has granted emergency authorization for other experimental coronavirus treatment, including remdesivir, which is an antiviral. 
  • For more stories like this, sign up here for Business Insider’s daily healthcare newsletter.

The US Food and Drug Administration just authorized emergency use of Eli Lilly’s experimental antibody treatment for COVID-19.

Doctors can now use the drug to treat coronavirus patients who have mild or moderate cases, but who are at high risk of getting sicker, Lilly said in a statement

The drug is one of dozens of antibody treatments currently being developed and studied to treat coronavirus patients. The drugmaker on October 7 submitted an application for its emergency approval.

The treatment is similar to the Regeneron antibody cocktail President Donald Trump received after being diagnosed with COVID-19. 

Read more: How 9 leading drugmakers are racing to develop antibody treatments

In clinical trials, the monoclonal antibody treatment showed promising results by reducing virus levels, symptoms, and hospitalizations in patients with mild to moderate cases. Researchers also found no serious side effects, the company said. The FDA’s authorization means high-risk patients showing mild to moderate symptoms can be treated with the drug.

The company plans to make up to one million doses of the drug available for use around the world by late December. Lilly said it will increase manufacturing significantly next year.

Monoclonal antibody treatments like Eli Lilly’s use synthetically manufactured antibodies similar to those produced by the human immune system and are widely regarded as the best measure for controlling the pandemic until a vaccine is widely available.

The treatment is delivered via intravenous transfusion. Antibody drugs are considered one of the most promising treatments to slow the coronavirus pandemic that’s now killed more than 1 million people worldwide.

Read more: The 10 most promising coronavirus treatments that could help curb the pandemic, even without a vaccine

“It made me better,” Trump said of his Regeneron antibody treatment in an interview with Fox Business on Thursday. “I didn’t feel great. I think I would’ve done it fine with no drugs, you don’t need drugs.” To be sure, Trump received two other treatments for COVID-19, so it’s impossible to say what effect Regeneron’s drug had.

In October, Eli Lilly CEO David Ricks said the company’s been in close communication with the White House’s Operation Warp Speed team about the ongoing treatment development. He also said the company wants patients to have “no or very, very low out-of-pocket costs anywhere in the world to receive this therapy.”

Loading Something is loading.

View original article here Source